Inhibition of IL-10 Production by Maternal Antibodies against Group B Streptococcus GAPDH Confers Immunity to Offspring by Favoring Neutrophil Recruitment
Group B Streptococcus (GBS) is the leading cause of neonatal pneumonia, septicemia, and meningitis. We have previously shown that in adult mice GBS glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an extracellular virulence factor that induces production of the immunosuppressive cytokine interleukin-10 (IL-10) by the host early upon bacterial infection. Here, we investigate whether immunity to neonatal GBS infection could be achieved through maternal vaccination against bacterial GAPDH. Female BALB/c mice were immunized with rGAPDH and the progeny was infected with a lethal inoculum of GBS strains. Neonatal mice born from mothers immunized with rGAPDH were protected against infection with GBS strains, including the ST-17 highly virulent clone. A similar protective effect was observed in newborns passively immunized with anti-rGAPDH IgG antibodies, or F(ab')2 fragments, indicating that protection achieved with rGAPDH vaccination is independent of opsonophagocytic killing of bacteria. Protection against lethal GBS infection through rGAPDH maternal vaccination was due to neutralization of IL-10 production soon after infection. Consequently, IL-10 deficient (IL-10−/−) mice pups were as resistant to GBS infection as pups born from vaccinated mothers. We observed that protection was correlated with increased neutrophil trafficking to infected organs. Thus, anti-rGAPDH or anti-IL-10R treatment of mice pups before GBS infection resulted in increased neutrophil numbers and lower bacterial load in infected organs, as compared to newborn mice treated with the respective control antibodies. We showed that mothers immunized with rGAPDH produce neutralizing antibodies that are sufficient to decrease IL-10 production and induce neutrophil recruitment into infected tissues in newborn mice. These results uncover a novel mechanism for GBS virulence in a neonatal host that could be neutralized by vaccination or immunotherapy. As GBS GAPDH is a structurally conserved enzyme that is metabolically essential for bacterial growth in media containing glucose as the sole carbon source (i.e., the blood), this protein constitutes a powerful candidate for the development of a human vaccine against this pathogen.
Vyšlo v časopise:
Inhibition of IL-10 Production by Maternal Antibodies against Group B Streptococcus GAPDH Confers Immunity to Offspring by Favoring Neutrophil Recruitment. PLoS Pathog 7(11): e32767. doi:10.1371/journal.ppat.1002363
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002363
Souhrn
Group B Streptococcus (GBS) is the leading cause of neonatal pneumonia, septicemia, and meningitis. We have previously shown that in adult mice GBS glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an extracellular virulence factor that induces production of the immunosuppressive cytokine interleukin-10 (IL-10) by the host early upon bacterial infection. Here, we investigate whether immunity to neonatal GBS infection could be achieved through maternal vaccination against bacterial GAPDH. Female BALB/c mice were immunized with rGAPDH and the progeny was infected with a lethal inoculum of GBS strains. Neonatal mice born from mothers immunized with rGAPDH were protected against infection with GBS strains, including the ST-17 highly virulent clone. A similar protective effect was observed in newborns passively immunized with anti-rGAPDH IgG antibodies, or F(ab')2 fragments, indicating that protection achieved with rGAPDH vaccination is independent of opsonophagocytic killing of bacteria. Protection against lethal GBS infection through rGAPDH maternal vaccination was due to neutralization of IL-10 production soon after infection. Consequently, IL-10 deficient (IL-10−/−) mice pups were as resistant to GBS infection as pups born from vaccinated mothers. We observed that protection was correlated with increased neutrophil trafficking to infected organs. Thus, anti-rGAPDH or anti-IL-10R treatment of mice pups before GBS infection resulted in increased neutrophil numbers and lower bacterial load in infected organs, as compared to newborn mice treated with the respective control antibodies. We showed that mothers immunized with rGAPDH produce neutralizing antibodies that are sufficient to decrease IL-10 production and induce neutrophil recruitment into infected tissues in newborn mice. These results uncover a novel mechanism for GBS virulence in a neonatal host that could be neutralized by vaccination or immunotherapy. As GBS GAPDH is a structurally conserved enzyme that is metabolically essential for bacterial growth in media containing glucose as the sole carbon source (i.e., the blood), this protein constitutes a powerful candidate for the development of a human vaccine against this pathogen.
Zdroje
1. BakerCJBarrettFFGordonRCYowMD 1973 Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr 82 724 729
2. BartonLLFeiginRDLinsR 1973 Group B beta hemolytic streptococcal meningitis in infants. J Pediatr 82 719 723
3. EdwardsMS 2006 Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 17 149 152
4. HeathPTSchuchatA 2007 Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol 21 411 424
5. JohriAKPaolettiLCGlaserPDuaMSharmaPK 2006 Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 4 932 942
6. ZangwillKMSchuchatAWengerJD 1992 Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 41 25 32
7. JordanHTFarleyMMCraigAMohle-BoetaniJHarrisonLH 2008 Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 27 1057 1064
8. FlueggeKSiedlerAHeinrichBSchulte-MoentingJMoennigMJ 2006 Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 117 e1139 1145
9. HajduABlystadHHoibyEAKloumanESchimmerB 2006 Unexpected increase in case fatality of invasive group B streptococcal infections in infants in Norway, January-July 2006. Euro Surveill 11: E060727 060722
10. HeathPTBalfourGWeisnerAMEfstratiouALamagniTL 2004 Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363 292 294
11. BaltimoreRS 2007 Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol 31 33 38
12. CastorMLWhitneyCGComo-SabettiKFacklamRRFerrieriP 2008 Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008 727505 727505
13. DoranKSNizetV 2004 Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol Microbiol 54 23 31
14. AmundsonNRFloresAEHillierSLBakerCJFerrieriP 2005 DNA macrorestriction analysis of nontypeable group B streptococcal isolates: clonal evolution of nontypeable and type V isolates. J Clin Microbiol 43 572 576
15. KongFLambertsenLMSlotvedHCKoDWangH 2008 Use of phenotypic and molecular serotype identification methods to characterize previously nonserotypeable group B streptococci. J Clin Microbiol 46 2745 2750
16. RamaswamySVFerrieriPFloresAEPaolettiLC 2006 Molecular characterization of nontypeable group B streptococcus. J Clin Microbiol 44 2398 2403
17. RamaswamySVFerrieriPMadoffLCFloresAEKumarN 2006 Identification of novel cps locus polymorphisms in nontypable group B Streptococcus. J Med Microbiol 55 775 783
18. MaioneDMargaritIRinaudoCDMasignaniVMoraM 2005 Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309 148 150
19. MargaritIRinaudoCDGaleottiCLMaioneDGhezzoC 2009 Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199 108 115
20. FriedmanCARobbinsKKTempleDMMillerCJRawsonJE 1996 Survival and neutrophil kinetics in infants with severe group B streptococcal disease treated with gamma globulin. J Perinatol 16 439 442
21. HillHRBohnsackJFMorrisEZAugustineNHParkerCJ 1988 Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol 141 3551 3556
22. HemmingVGMcCloskeyDWHillHR 1976 Pneumonia in the neonate associated with group B streptococcal septicemia. Am J Dis Child 130 1231 1233
23. QuiranteJCeballosRCassadyG 1974 Group B beta-hemolytic streptococcal infection in the newborn. I. Early onset infection. Am J Dis Child 128 659 665
24. AndersonDCHughesBJSmithCW 1981 Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine. J Clin Invest 68 863 874
25. BuhrerCGraulichJStibenzDDudenhausenJWObladenM 1994 L-selectin is down-regulated in umbilical cord blood granulocytes and monocytes of newborn infants with acute bacterial infection. Pediatr Res 36 799 804
26. KoenigJMYoderMC 2004 Neonatal neutrophils: the good, the bad, and the ugly. Clin Perinatol 31 39 51
27. CancelierACPetronilhoFReinkeAConstantinoLMachadoR 2009 Inflammatory and oxidative parameters in cord blood as diagnostic of early-onset neonatal sepsis: a case-control study. Pediatr Crit Care Med 10 467 471
28. RomagnoliCFrezzaSCingolaniADe LucaAPuopoloM 2001 Plasma levels of interleukin-6 and interleukin-10 in preterm neonates evaluated for sepsis. Eur J Pediatr 160 345 350
29. MadureiraPBaptistaMVieiraMMagalhaesVCameloA 2007 Streptococcus agalactiae GAPDH is a virulence-associated immunomodulatory protein. J Immunol 178 1379 1387
30. JonesNBohnsackJFTakahashiSOliverKAChanMS 2003 Multilocus sequence typing system for group B streptococcus. J Clin Microbiol 41 2530 2536
31. LamyMCDramsiSBilloetAReglier-PoupetHTaziA 2006 Rapid detection of the “highly virulent” group B Streptococcus ST-17 clone. Microbes Infect 8 1714 1722
32. PoyartCReglier-PoupetHTaziABilloetADmytrukN 2008 Invasive group B streptococcal infections in infants, France. Emerg Infect Dis 14 1647 1649
33. SeifertKNMcArthurWPBleiweisASBradyLJ 2003 Characterization of group B streptococcal glyceraldehyde-3-phosphate dehydrogenase: surface localization, enzymatic activity, and protein-protein interactions. Can J Microbiol 49 350 356
34. CornacchionePScaringiLFettucciariKRosatiESabatiniR 1998 Group B streptococci persist inside macrophages. Immunology 93 86 95
35. MonteiroGCHirataRJrAndradeAFMattos-GuaraldiALNagaoPE 2004 Surface carbohydrates as recognition determinants in non-opsonic interactions and intracellular viability of group B Streptococcus strains in murine macrophages. Int J Mol Med 13 175 180
36. QuachDvan SorgeNMKristianSABryanJDShelverDW 2009 The CiaR response regulator in group B Streptococcus promotes intracellular survival and resistance to innate immune defenses. J Bacteriol 191 2023 2032
37. Valenti-WeigandPBenkelPRohdeMChhatwalGS 1996 Entry and intracellular survival of group B streptococci in J774 macrophages. Infect Immun 64 2467 2473
38. LiuGYNizetV 2004 Extracellular virulence factors of group B Streptococci. Front Biosci 9 1794 1802
39. Marshall-ClarkeSReenDTaskerLHassanJ 2000 Neonatal immunity: how well has it grown up? Immunol Today 21 35 41
40. LemkeHCoutinhoALangeH 2004 Lamarckian inheritance by somatically acquired maternal IgG phenotypes. Trends Immunol 25 180 186
41. BelderbosMEvan BleekGMLevyOBlankenMOHoubenML 2009 Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol 133 228 237
42. ChelvarajanLPopaDLiuYGetchellTVStrombergAJ 2007 Molecular mechanisms underlying anti-inflammatory phenotype of neonatal splenic macrophages. J Leukoc Biol 82 403 416
43. KollmannTRCrabtreeJRein-WestonABlimkieDThommaiF 2009 Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 183 7150 7160
44. SunCMDeriaudELeclercCLo-ManR 2005 Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 22 467 477
45. GenoveseFMancusoGCuzzolaMBiondoCBeninatiC 1999 Role of IL-10 in a neonatal mouse listeriosis model. J Immunol 163 2777 2782
46. RainsfordEReenDJ 2002 Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. Br J Haematol 116 702 709
47. CusumanoVGenoveseFMancusoGCarboneMFeraMT 1996 Interleukin-10 protects neonatal mice from lethal group B streptococcal infection. Infect Immun 64 2850 2852
48. FiorentinoDFZlotnikAMosmannTRHowardMO'GarraA 1991 IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 3815 3822
49. FiorentinoDFZlotnikAVieiraPMosmannTRHowardM 1991 IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146 3444 3451
50. MooreKWde Waal MalefytRCoffmanRLO'GarraA 2001 Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 683 765
51. SaraivaMO'GarraA 2010 The regulation of IL-10 production by immune cells. Nat Rev Immunol 10 170 181
52. BerkmanNJohnMRoesemsGJosePJBarnesPJ 1995 Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J Immunol 155 4412 4418
53. KopydlowskiKMSalkowskiCACodyMJvan RooijenNMajorJ 1999 Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 163 1537 1544
54. Marfaing-KokaAMaravicMHumbertMGalanaudPEmilieD 1996 Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. Int Immunol 8 1587 1594
55. Zuany-AmorimCCreminonCNeversMCNahoriMAVargaftigBB 1996 Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. J Immunol 157 377 384
56. Zuany-AmorimCHaileSLeducDDumareyCHuerreM 1995 Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest 95 2644 2651
57. BelkaidYHoffmannKFMendezSKamhawiSUdeyMC 2001 The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194 1497 1506
58. MurphyMLWilleUVillegasENHunterCAFarrellJP 2001 IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31 2848 2856
59. ReedSGBrownellCERussoDMSilvaJSGrabsteinKH 1994 IL-10 mediates susceptibility to Trypanosoma cruzi infection. J Immunol 153 3135 3140
60. RoqueSNobregaCAppelbergRCorreia-NevesM 2007 IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy. J Immunol 178 8028 8035
61. SilvaRAAppelbergR 2001 Blocking the receptor for interleukin 10 protects mice from lethal listeriosis. Antimicrob Agents Chemother 45 1312 1314
62. CleatPHWellsCCoidCR 1984 Electron microscopic evidence of antibody entry into neutrophils after phagocytosis of highly virulent group B streptococci. J Gen Microbiol 130 3059 3061
63. SchuitKEDeBiasioR 1980 Kinetics of phagocyte response to group B streptococcal infections in newborn rats. Infect Immun 28 319 324
64. LevyOMartinSEichenwaldEGanzTValoreE 1999 Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 104 1327 1333
65. DerkxBMarchantAGoldmanMBijlmerRvan DeventerS 1995 High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171 229 232
66. LehmannAKHalstensenASornesSRokkeOWaageA 1995 High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 63 2109 2112
67. SchragSJZywickiSFarleyMMReingoldALHarrisonLH 2000 Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 342 15 20
68. SchuchatA 1998 Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 11 497 513
69. Abu-AsabMSLaassriMAmriH 2010 Algorithmic assessment of vaccine-induced selective pressure and its implications on future vaccine candidates. Adv Bioinformatics 2010 178069 178069
70. HaasRMeyerTF 1986 The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion. Cell 44 107 115
71. HelmRASeifertHS 2009 Pilin antigenic variation occurs independently of the RecBCD pathway in Neisseria gonorrhoeae. J Bacteriol 191 5613 5621
72. HillSADaviesJK 2009 Pilin gene variation in Neisseria gonorrhoeae: reassessing the old paradigms. FEMS Microbiol Rev 33 521 530
73. KlineKACrissAKWallaceASeifertHS 2007 Transposon mutagenesis identifies sites upstream of the Neisseria gonorrhoeae pilE gene that modulate pilin antigenic variation. J Bacteriol 189 3462 3470
74. TushinskiRJOliverITGuilbertLJTynanPWWarnerJR 1982 Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 28 71 81
75. HeRQYangMDZhengXZhouJX 1995 Isolation and some properties of glycated D-glyceraldehyde-3-phosphate dehydrogenase from rabbit muscle. Biochem J 309 Pt 1 133 139
76. MountassifDBaibaiTFourratLMoutaouakkilAIddarA 2009 Immunoaffinity purification and characterization of glyceraldehyde-3-phosphate dehydrogenase from human erythrocytes. Acta Biochim Biophys Sin (Shanghai) 41 399 406
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 11
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Multiple Candidate Effectors from the Oomycete Pathogen Suppress Host Plant Immunity
- The Splicing Factor Proline-Glutamine Rich (SFPQ/PSF) Is Involved in Influenza Virus Transcription
- A TNF-Regulated Recombinatorial Macrophage Immune Receptor Implicated in Granuloma Formation in Tuberculosis
- SH3 Domain-Mediated Recruitment of Host Cell Amphiphysins by Alphavirus nsP3 Promotes Viral RNA Replication